Skip to main content
$15.25 $0.32 (2.1%)

04:00 PM EDT on 09/17/21

Cara Therapeutics (NASDAQ:CARA)

CAPS Rating: 3 out of 5

Current Price $15.25 Mkt Cap $747.8M
Open $14.97 P/E Ratio 87.62
Prev. Close $15.25 Div. (Yield) $0.00 (0.0%)
Daily Range $14.71 - $15.30 Volume 1,692,642
52-Wk Range $11.22 - $29.65 Avg. Daily Vol. 2,147,486


How do you think NASDAQ:CARA will perform against the market?

Add Stock to CAPS Watchlist

All Players

80 Outperform
6 Underperform

All-Star Players

12 Outperform
1 Underperform

Wall Street

0 Outperform
0 Underperform

Top NASDAQ:CARA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

odocoileus (57.81)
Submitted February 02, 2020

I got into CARA too early, but so far I haven't seen much to change my opinion on it. They failed their secondary endpoints in their last PH II trial, but they achieved their primary endpoint. The market was fairly harsh on these results. CARA is a… More

Jflagg1991 (75.07)
Submitted July 19, 2018

Heading down on offering and needs news to stay up


Fools bullish on NASDAQ:CARA are also bullish on:

Fools bearish on NASDAQ:CARA are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about CARA.


Member Avatar mdriver78 (75.43) Submitted: 6/16/2021 3:04:26 PM : Outperform Start Price: $13.74 NASDAQ:CARA Score: +7.42

CARA) started out in life as a company developing alternative pain medications. These days, it’s refined its pipeline to deal with pruritus, which is a fancy medical term for itching.

Constant itchiness can be a big health and quality of life problem, and the causes aren’t always dermatological. A wide variety of conditions can cause a constant, sometimes severe itch.

That includes millions of people in the US with chronic kidney disease. It can cause extremely itchy skin, especially in end stage disease requiring dialysis.

Cara is developing a drug called CR845 to treat chronic kidney disease related pruritus. The drug targets Kappa opioid receptors without producing the addictive side effects of other opioid drugs. Cara was previously developing CR845 for pain management, however, the drug failed in this application.

But CR845 has shown much better results in chronic kidney disease related pruritus. In Phase 3 trials, the compound demonstrated a significant itching reduction in injected patients versus placebo in patients with chronic kidney disease who were on dialysis and had moderate to severe pruritus. The reduction in itch proved to be a big improvement in patient quality of life.

Close to half a million people in the US are on dialysis for renal disease. Of these, some 40% suffer from pruritus. This means Cara has a big market it can target should the FDA approve its drug on its PDUFA date of August 23rd, 2021.

Moreover, the company could one day also target the much larger non dialysis dependent chronic kidney disease segment, which is some 30 million people. In this population, approximately 40% also suffer from moderate to severe pruritus. Cara is planning to put an oral form of CR845 into Phase 3 clinical trials in this group in the second half of the year. Moreover, the company plans to initiate an additional Phase 3 trial in atopic dermatitis at the end of the year. It also expects to report top line Phase 2 data in pruritus associated with liver disease in the second half of this year.

If approved, CR845 will be the first drug specifically approved for this indication. It’s mechanism of action is also unique compared to things like topical steroids: it directly interacts with the cellular receptors responsible for transmitting that itching feeling. The market size for this drug, just in the dialysis patient population, could be larger than Cara’s current market cap.

Overseas, Cara would also be in line for large milestone payments if CR845 is approved in Europe and Japan. Vifor Fresenius has licensed the drug for the EU, and the deal includes up to $440 million in commercial milestone payments as well as tiered sales royalties. In Japan, Maruishi Pharmaceutical is also licensing the drug and paying Cara on a tiered royalty basis, along with $10 million in commercial milestone commitments. The large size of these deals underscores the large market potential of Cara’s drug.

Increasing option activity may be sign of drug development revelation.


Member Avatar awisecrackin (48.88) Submitted: 3/24/2020 10:03:16 AM : Outperform Start Price: $11.70 NASDAQ:CARA Score: -58.71

Focused on common annoyances of skin issues like psorisis. Also, has a hand in developing medications based on marijuana. Has a large deal already with a foreign pharm company.


Member Avatar odocoileus (57.81) Submitted: 2/2/2020 5:13:45 PM : Outperform Start Price: $20.37 NASDAQ:CARA Score: -113.84

I got into CARA too early, but so far I haven't seen much to change my opinion on it. They failed their secondary endpoints in their last PH II trial, but they achieved their primary endpoint. The market was fairly harsh on these results. CARA is a one-trick pony, and I think the market tends to be a little more nervous on mixed results for these types of companies. But given that there really is not much else out there for pruritis I don't see these results scuttling FDA approval if the PH III KALM-3 trials are successful. Yeah, big if, but given their prior results, I'm banking on success here. And we should know in a few months. Then it's off to the races. Before concentrating on pruritis, CARA did trials for non-addictive pain relief with some mixed results. This is where the real money is, and if they get this first approval under their belt they should have some breathing room to get back to these trials--if they don't get bought out first.


Find the members with the highest scoring picks in CARA.

Score Leader


slingermoonsine (< 20) Score: +288.41

The Score Leader is the player with the highest score across all their picks in CARA.

Member Name Member
Call Time
Score Commentary
ultrasounddoc < 20 4/28/2014 Underperform 5Y $13.94 +7.68% +136.31% +128.64 0 Comment
bonznstonz 43.93 3/17/2016 Outperform 3Y $4.76 +215.34% +117.49% +97.85 0 Comment
jayzmrmn 82.21 7/12/2016 Outperform 3Y $5.18 +189.77% +105.66% +84.11 1 Comment
TheIzzishWizzy 85.67 6/17/2016 Outperform 5Y $5.05 +197.23% +113.62% +83.61 0 Comment
OttoBismarck 99.42 10/17/2018 Underperform 5Y $20.27 -25.95% +57.52% +83.47 0 Comment
surfco3 91.92 6/16/2016 Outperform 5Y $5.10 +194.31% +113.04% +81.27 0 Comment
Jflagg1991 75.07 7/19/2018 Underperform 3W $19.65 -23.61% +57.65% +81.26 1 Comment
dundara 96.76 9/6/2016 Outperform 1Y $5.40 +177.96% +102.11% +75.85 0 Comment
MaBrandao < 20 3/21/2016 Outperform 1Y $5.35 +180.56% +116.60% +63.96 0 Comment
Clopperc < 20 3/7/2016 Outperform 3W $5.37 +179.52% +121.74% +57.77 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for CARA.